These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12939917)

  • 1. Should health care money in South Africa be spent on drotrecogin alfa?
    Taylor B; Burns D; van de Wal BW; MBewu T; Keeton GR
    S Afr Med J; 2003 Jul; 93(7):500-1. PubMed ID: 12939917
    [No Abstract]   [Full Text] [Related]  

  • 2. Drotrecogin alfa (activated) in South African private hospital ICUs.
    Hodgson RE; Williams PG; Foden AP; Grolman D
    S Afr Med J; 2003 Jul; 93(7):474-5. PubMed ID: 12939910
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of drotrecogin alfa (activated) on resource use and implications for reimbursement.
    Dasta JF; Cooper LM
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):216S-222S. PubMed ID: 12492228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The story of drotrecogin alfa - evidence-based or evidence-biased?
    Wiseman R; Blockman M
    S Afr Med J; 2011 Dec; 102(1):8. PubMed ID: 22273122
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question.
    Banks SM; Gerstenberger E; Eichacker PQ; Natanson C
    Crit Care Med; 2003 Jan; 31(1):308-9. PubMed ID: 12545035
    [No Abstract]   [Full Text] [Related]  

  • 6. Appraisal of treatment for severe sepsis in intensive care units.
    Burchell M; Ruiz F; Barnett D
    Ann R Coll Surg Engl; 2005 Jul; 87(4):283-4. PubMed ID: 16888847
    [No Abstract]   [Full Text] [Related]  

  • 7. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    Morris PE
    Am J Crit Care; 2003 Mar; 12(2):94-7. PubMed ID: 12625165
    [No Abstract]   [Full Text] [Related]  

  • 8. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    McEvoy M
    Am J Crit Care; 2003 Sep; 12(5):398; author reply 398. PubMed ID: 14503421
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
    Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
    Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based disease management in medication-use evaluation: application to drotrecogin alfa (activated) in severe sepsis.
    Durthaler JM; Ernst FR
    Am J Health Syst Pharm; 2006 Aug; 63(15):1453-60. PubMed ID: 16849712
    [No Abstract]   [Full Text] [Related]  

  • 11. Drotrecogin alfa (activated) for severe sepsis.
    Drug Ther Bull; 2006 Jan; 44(1):5-8. PubMed ID: 16425899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of drotrecogin alfa (activated).
    Tsitanidis J
    Crit Care Med; 2003 Sep; 31(9):2414-5; author reply 2415. PubMed ID: 14501983
    [No Abstract]   [Full Text] [Related]  

  • 13. Management challenge with drotrecogin alfa (activated).
    Vanscoy GJ
    Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S23-9. PubMed ID: 11885411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simplified pharmacoeconomics of critical care and severe sepsis.
    Ernst FR; Levy H; Qualy RL
    J Intensive Care Med; 2007; 22(5):283-93. PubMed ID: 17895486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC).
    Chalfin DB; Teres D; Rapoport J
    Crit Care Med; 2003 Jan; 31(1):306-8. PubMed ID: 12545034
    [No Abstract]   [Full Text] [Related]  

  • 17. Practical aspects of treatment with drotrecogin alfa (activated).
    Camporota L; Wyncoll D
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S7. PubMed ID: 18269694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Green C; Dinnes J; Takeda AL; Cuthbertson BH
    Int J Technol Assess Health Care; 2006; 22(1):90-100. PubMed ID: 16673685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
    Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of drotrecogin alfa (activated) in older patients with severe sepsis.
    Alexander SL; Ernst FR
    Pharmacotherapy; 2006 Apr; 26(4):533-8. PubMed ID: 16553513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.